Biocon Biologics completes integration of Viatris Biosimilars’ business in North America

Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris

Biocon Biologics announces leadership appointments

USFDA accepts biologics license application for GC Biopharma's GC5107B

Biocon Biologics gets EMA’s positive opinion for an ophthalmology product

USFDA completes two cGMP inspections at Biocon Biologics' insulins facility in Malaysia

The agency issued a Form 483 with 6 observations for Drug Substance, Drug Product units and Quality Control laboratories

Tillotts Pharma and TVM Capital form Mage Biologics to develop oral antibody therapy for ulcerative colitis

Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis

Astellas receives FDA priority review for Zolbetuximab biologics license application

Astellas stands on the forefront of healthcare change to turn innovative science into value for patients

Biocon Biologics expands footprint in emerging markets

Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries

Biocon Biologics' Hulio Biosimilar to Humira now available in the US

The launch of HULIO in the United States is an important milestone for Biocon Biologics

Samsung Biologics and Pfizer collaborate for long-term manufacturing of biosimilars portfolio

Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio